The anti-GpIIb-IIIa agents: Fundamental and clinical aspects

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 285-293

  Coller, Barry S ^a   Anderson, Keaven M ^b   Weisman, Harlan F ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Angioplasty; GPIIb IIIa; Integrin Receptors; Myocardial Infarction; Platelets; Thrombosis; Unstable Angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTEGRIN RECEPTOR; LAMIFIBAN; LEFRADAFIBAN; LY 297141; MONOCLONAL ANTIBODY; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; PRADAFIBAN; SDZ GPI 562; THROMBOCYTE ANTIGEN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

ANGINA PECTORIS; ANGIOPLASTY; ANIMAL MODEL; CLINICAL TRIAL; CONFERENCE PAPER; HEART INFARCTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE; THROMBOSIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MULTICENTER STUDIES; OLIGOPEPTIDES; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT FUSION PROTEINS; THROMBOSIS; TYROSINE;

EID: 0029903401     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217309     Document Type: Article

References (36)

1. Coller BS: Platelets in cardiovascular thrombosis and thrombolysis; in Fozzard HA. Jennings RB, Katz AM. Morgan HE. Haber E (eds): The Heart and Cardiovascular System. New York, Raven Press, 1992, pp 219-273.
2. Coller BS, Anderson K, Weisman HF: Inhibitors of Platelet Aggregation: GPIIb/IlIa Antagonists; in Braunwald E. (ed): Update 4, Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, W.B. Saunders Co. 1995, pp 1-10.
3. Fernandez Ortiz A. Badimon JJ, Falk E, Fuster V. Meyer B. Mailhac A, Weng D, Shah PK. Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-1569.
4. Hynes RO. Integrins: versatility, modulation and signalling in cell adhesion. Cell 1994;69:11-25.
5. Pytela R. Pierschbacher MD, Ginsberg MH. Plow EF. Ruoslahti E. Platelet membrane glycoprotein Ilb/IIIa: Member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986;231:1559-1562.
6. Cook NS. Kottirsch G, Zerwes H. Platelet glycoprotein Ilb/IIIa antagonists. Drugs of Future 1994;19:135-159.
7. Cox D. Aoki T, Seki J, Motoyama Y. Yoshida K. The pharmacology of integrins. Med Res Rev 1994:14:195-228.
8. Fclding-Habermann B. Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864-868.
9. Coller BS, Seligsohn U, Peretz H. Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994;31:301-311.
10. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet GPIIb/llIa complex. J Clin Invest 1985;76:101-108.
11. Knight DM, Wagner C. Jordan R. MeAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoelonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995;32:1271-1281.
12. Coller BS, Cheresh DA. Asch E, Seiigsolm U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab Patients with Glanzmann thrombasthenia in Israel. Blood 1991;77:75-83.
13. Coller BS. Scudder LE, Beer J. Gold HK. Folts JD. Cabagnaro J. Jordan R, Wagner C, Iuliucci J. Knight D. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991:614:193-213.
14. Coller BS. Inhibitors of the platelet glycoprotein Ilb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Art Dis 1992;3:1016-1029.
15. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
16. Topol EJ, Calif! RM. Weismann HF, Ellis SG, Tcheng JE. Worley S. Ivanhoe R. George BS, Fintel D, Weston M. Randomized trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994:343:881-886.
17. Lincoff AM, Tcheng JE, Bass TA. Popma JJ, Teirstein PS, Kleiman NS, Weisman HF, Musco NH. Cabot CF. Berdan LGA. Multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. JAm Coll Cardiol 1995;80A(Abstract)
18. Ferguson JJI. EPILOG and CAPTURE trials halted because of positive results. Circulation 1996:93:637
19. Lincoff AM. Evaluation of PTCA to improve long-term outcomes by c7E3 glycoprotein Ilb/IIIa receptor blockade. Presented at the 45th Annual Scientific Session, American College of Cardiology, March 1996. Orlando. FL. Personal Communication.(1996)
20. Simoons ML. Refractory unstable angina: reduction of events by c7E3: The CAPTURE study. Presented at the 45th Annual Scientific Session, American College of Cardiology. March 1996, Orlando. FL.
21. Moliterno DJ. Califf RM. Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein Ilb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-562.
22. Ammar T. Sarier K. Coller BS. Activated clotting lime of heparinized blood is increased by in vitro platelet glycoprotein Ilb/IIIa receptor blockade with antibody c7E3 Fab. Thromb Haemostas 1995;73:1313(Abstract)
23. Reverter JC, Béguin S, Kessels H, Kumar R. Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced, thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;(in press)
24. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:332-342.
25. Cox AD, Devine DV. Factor XHIa binding to activated platelets is mediated through activation of glycoprotein Ilb-IIIa. Blood 1994;83:1006-1016.
26. Schwartz SM. Serum-derived growth factor is thrombin? J Clin Invest 1993;91:4.
27. Choi ET, Engel L, Callow AD, Sun S. Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avb3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vase Surg 1994;19:125-134.
28. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994;90:2203-2206.
29. Christopoulos CG. Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimaeric antibody. Br J Haematol 1994;87:650-652.
30. Kereiakes D. Personal Communication.
31. Wagner CL, Cunningham MR, Wyand MS, Weisman HF. Coller BS, Jordan RE. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys. Thromb Haemostas 1995;73:1313(Abstract)
32. Christopoulos C, Mackic I. Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein Ilb-IIIa. Blood Coagul Fibrinolysis 1993;4:729-737.
33. Jordan RE, Wagner CL, Mascelli M, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BS: Preclinical development of c7E3 Fab; a mouse/human chimeric monclonal antibody frag ment that inhibits platelet function by blockade of GPIlb/IIIa receptors with observations on the Immunogenicity of c7E3 Fab in humans; in Horton MD MA (ed): Adhesion Receptors as Therapeutic Targets. Boca Raton, CRC Press, Inc. 1996, pp 281-305.
34. Horrigan MC, Tchcng TE, Califf RM, Kitt M. Lorenz T, Sigmon KA. Lincoff M, Topol EJ. Maximal benefit of integrelin platelet Ilb/IIIa blockade 6-24 hours after therapy: Results of the IMPACT-II trial. J Am Coll Cardiol 1996:27:55A(Abstract)
35. King SB I. Administration of tirofiban (MK-0383) will reduce the incidence of adverse cardiac outcomes following PTCA/PCA (RESTORE). Presented at the 45th Annual Scientific Session, American College of Cardiology, March 1996, Orlando, FL.
36. Coller BS, Scudder LE, Lang D. A rapid, whole blood, bedside assay to monitor platelet glyco protein (GP) Ilb/IIIa blockade. Blood 1994:84:474a(Abstract)